Compare BlackBerry Limited (BB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs TG Therapeutics Inc — how do they compare? BlackBerry Limited trades at $8.89 (market cap $5.27B), while TG Therapeutics Inc trades at $50.01 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, BlackBerry Limited nearer its low. Which is the better fit depends on your goals.
| BB | TGTX | |
|---|---|---|
Market Cap | $5.27B | $7.64B |
Sector | Technology | Health |
52-Week High | $12.81 | $59.06 |
52-Week Low | $3.15 | $26.94 |
Enterprise Value | $5.14B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $8.87, up 0.45% in the last session, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beats, including Q1 2026 EPS of $0.06 versus $0.05 expected, highlight operational momentum. Revenue for 2025 was $534.90M, with a net loss of -$79M, though 2026 guidance projects a return to profitability. Positive cash flow from operations of $16.50M in 2025 marks an improvement from prior years.
The stock offers speculative upside driven by QNX and secure communications growth, with a consensus price target of $10.50. However, high valuation ratios like a P/E of 89.8 and execution risks temper optimism. Investor sentiment is mixed, with most analysts rating Hold, citing premium valuation concerns amid a competitive landscape.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
